Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2023 | Avatrombopag in patients with early versus chronic immune thrombocytopenia

Hanny Al-Samkari • 9 Dec 2023
ASH 2023
Immune Thrombocytopenia Non-Malignant Avatrombopag Eltrombopag

Hanny Al-Samkari, MD, Massachusetts General Hospital, Boston, MA, discusses a study of avatrombopag in patients with early versus chronic immune thrombocytopenia (ITP). At present, this drug, which is considered to be more convenient than eltrombopag due to its lower rate of side effects, is only approved in the chronic form of ITP. However, this study showed its comparable efficacy and safety in those patients with early ITP. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Consultancy: Agios, Pharmacosmos, Sobi, Novartis, Amgen, argenx, Moderna
Research Funding: Agios, Sobi, Amgen

More from Hanny Al-Samkari

1:09
Emerging treatment options for refractory immune thrombocytopenia
Hanny Al-Samkari • 9 Dec 2023
1:25
Improving the sensitivity of platelet autoantibody testing for ITP diagnosis
Hanny Al-Samkari • 9 Dec 2023
1:31
Mitapivat improves work/school attendance in patients with pyruvate kinase deficiency
Hanny Al-Samkari • 9 Dec 2023
2:55
The role of anticoagulation and antiplatelet therapy in hereditary hemorrhagic telangiectasia
Hanny Al-Samkari • 25 Jun 2023

Related Videos

2:01
The MDT in the new era of gene therapy for hemoglobinopathies
Mattia Algeri • 15 Apr 2024
2:38
Treosulfan vs busulfan conditioning in pediatric patients with non-malignant diseases
Rita Beier • 15 Apr 2024
2:18
A global view of transfusion-dependent thalassemia: standard of care, outcomes, and unmet needs
Ali Taher • 15 Apr 2024
1:24
The future of CAR T-reg cells: organ transplantation & autoimmune disease
Zinaida Good • 9 Apr 2024
The content of VJHemOnc is intended for healthcare professionals